Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Zacks News
Are Medical Stocks Lagging Abcam (ABCM) This Year?
by Zacks Equity Research
Here is how Abcam PLC Sponsored ADR (ABCM) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PRFZ
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.
The Zacks Analyst Blog Highlights DraftKings, Celsius Holdings, Marriott International, Copart and Exact Sciences
by Zacks Equity Research
DraftKings, Celsius Holdings, Marriott International, Copart and Exact Sciences are part of the Zacks top Analyst Blog.
Top 5 Non-Tech Nasdaq Winners of 1H With More Upside Left
by Nalak Das
We have narrowed our search to five Nasdaq Composite listed non-technology stocks. These are: CELH, DKNG, CPRT, EXAS, MAR.
Here's Why You Should Buy Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.
Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Walgreens Boots' (WBA) Q3 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) U.S. Healthcare business expands, owing to key contract wins, continued partnership growth and a strong focus on execution.
Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strategic executions on the United States and the international front is likely to drive Walgreens' (WBA) Q3 revenues.
Are You Looking for a Top Momentum Pick? Why Exact Sciences (EXAS) is a Great Choice
by Zacks Equity Research
Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Exact Sciences (EXAS) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
by Zacks Equity Research
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PRFZ
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Zacks.com featured highlights ColgatePalmolive, BigCommerce and Exact Sciences
by Zacks Equity Research
ColgatePalmolive, BigCommerce and Exact Sciences have been highlighted in this Screen of The Week article.